Tenofovir - CONRAD

Drug Profile

Tenofovir - CONRAD

Alternative Names: (R)-PMPA; GS 1278; PMPA

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centre for the AIDS Programme of Research in South Africa; Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer CONRAD; Gilead Sciences; Hanmi Pharmaceutical; National Institute of Allergy and Infectious Diseases
  • Class Adenine nucleotides; Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • No development reported Hepatitis B

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in South Korea
  • 13 Sep 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV Infections in November 2018 , (NCT03670355)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, In volunteers) in Dominican Republic (Vaginal, Ring)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top